By Steve Usdin
FDA's approval of Zohydro ER hydrocodone bitartrate from Zogenix
Inc. has reignited debates about the best ways to balance the needs of
pain patients and concerns about opioid drug addiction, abuse and overdoses.
Calls from powerful politicians to reverse FDA's decision to approve Zohydro
have also revived concerns about the politicization of drug oversight.
The voices of pain patients
have been drowned out by Zohydro's critics, in part because critics of FDA's
approval have made extraordinary claims about the drug's potency and abuse